RT Journal Article
SR Electronic
T1 Mechanistic modeling of SARS-CoV-2 immune memory, variants, and vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.31.21258018
DO 10.1101/2021.05.31.21258018
A1 Cohen, Jamie A.
A1 Stuart, Robyn M.
A1 Núñez, Rafael C.
A1 Wagner, Bradley
A1 Chang, Stewart
A1 Rosenfeld, Katherine
A1 Kerr, Cliff C.
A1 Famulare, Michael
A1 Klein, Daniel J.
YR 2021
UL http://medrxiv.org/content/early/2021/06/01/2021.05.31.21258018.abstract
AB Early waves of the SARS-CoV-2 pandemic were driven by importation events and subsequent policy responses. However, epidemic dynamics in 2021 are largely driven by the spread of more transmissible and/or immune-evading variants, which in turn are countered by vaccination programs. Here we describe updates to the methodology of Covasim (COVID-19 Agent-based Simulator) to account for immune trajectories over time, correlates of protection, co-circulation of different variants and the roll-out of multiple vaccines. We have extended recent work on neutralizing antibodies (NAbs) as a correlate of protection to account for protection against infection, symptomatic COVID-19, and severe disease using a joint estimation approach. We find that NAbs are strongly correlated with infection blocking and that natural infection provides stronger protection than vaccination for the same level of NAbs, though vaccines typically produce higher NAbs. We find only relatively weak correlations between NAbs and the probability of developing symptoms given a breakthrough infection, or the probability of severe disease given symptoms. A more refined understanding of breakthrough infections in individuals with natural and vaccine-derived immunity will have implications for timing of booster vaccines, the impact of emerging variants of concern on critical vaccination thresholds, and the need for ongoing non-pharmaceutical interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the Bill and Melinda Gates Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code are freely available. https://github.com/amath-idm/COVID-Immune-Modeling